SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis.

[1]  J. Ortonne,et al.  The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression , 2011, Pigment cell & melanoma research.

[2]  Mikala Egeblad,et al.  Dynamic interplay between the collagen scaffold and tumor evolution. , 2010, Current opinion in cell biology.

[3]  N. Lemke,et al.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. , 2010, Neuro-oncology.

[4]  A. Marshall,et al.  Lost in migration , 2010, Nature Biotechnology.

[5]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[6]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[7]  Michael K. Wendt,et al.  Mechanisms of the epithelial-mesenchymal transition by TGF-beta. , 2009, Future oncology.

[8]  F. Portillo,et al.  The morphological and molecular features of the epithelial-to-mesenchymal transition , 2009, Nature Protocols.

[9]  T. Lah,et al.  Post-Translational Regulation of Cathepsin B, but not of Other Cysteine Cathepsins, Contributes to Increased Glioblastoma Cell Invasiveness In Vitro , 2009, Pathology & Oncology Research.

[10]  Keith March,et al.  IFATS Collection: Combinatorial Peptides Identify α5β1 Integrin as a Receptor for the Matricellular Protein SPARC on Adipose Stromal Cells , 2008, Stem cells.

[11]  E. Sage,et al.  The Copper Binding Domain of SPARC Mediates Cell Survival in Vitro via Interaction with Integrin β1 and Activation of Integrin-linked Kinase* , 2008, Journal of Biological Chemistry.

[12]  R. Timpl,et al.  Mapping of SPARC/BM-40/Osteonectin-binding Sites on Fibrillar Collagens* , 2008, Journal of Biological Chemistry.

[13]  R. Assoian,et al.  Growth control by intracellular tension and extracellular stiffness. , 2008, Trends in cell biology.

[14]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[15]  G. Taraboletti,et al.  Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. , 2008, Neoplasia.

[16]  Y. Shintani,et al.  Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1 , 2008, The Journal of cell biology.

[17]  B. Gardiner,et al.  Osteonectin downregulates E‐cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype , 2007, International journal of cancer.

[18]  H. Juan,et al.  Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition , 2007, Oncogene.

[19]  O. Podhajcer,et al.  Proteomic analysis identified N‐cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells , 2007, Proteomics.

[20]  Mariano J. Alvarez,et al.  SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. , 2007, The Journal of investigative dermatology.

[21]  D. Bigner,et al.  Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases , 2007, Oncogene.

[22]  Bonnie F. Sloane,et al.  Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-β1-signaling and upregulation of cathepsin B , 2007, Biological chemistry.

[23]  A. Sánchez-Aguilera,et al.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.

[24]  Brady T. West,et al.  Linear Mixed Models: A Practical Guide Using Statistical Software , 2006 .

[25]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[26]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[27]  P. Abbe,et al.  SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. , 2006, Cancer research.

[28]  F. Arnett,et al.  Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. , 2006, Arthritis and rheumatism.

[29]  T. Krieg,et al.  Contact of high‐invasive, but not low‐invasive, melanoma cells to native collagen I induces the release of mature cathepsin B , 2006, International journal of cancer.

[30]  Shaoyi Jiang,et al.  Identifying the SPARC binding sites on collagen I and procollagen I by atomic force microscopy. , 2005, Analytical chemistry.

[31]  Mariano J. Alvarez,et al.  Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. , 2005, Cancer research.

[32]  J. Kang,et al.  The Amyloid-β Peptide Suppresses Transforming Growth Factor-β1-induced Matrix Metalloproteinase-2 Production via Smad7 Expression in Human Monocytic THP-1 Cells* , 2005, Journal of Biological Chemistry.

[33]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[34]  William P Schiemann,et al.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.

[35]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[36]  Bonnie F. Sloane,et al.  Pericellular cathepsin B and malignant progression , 2003, Cancer and Metastasis Reviews.

[37]  J. Davidson,et al.  SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. , 2003, The Journal of investigative dermatology.

[38]  Jody A. Vandergriff,et al.  Erratum: PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification (Nucleic Acids Research (2003) vol. 31 (334-341)) , 2003 .

[39]  N. Lemke,et al.  Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.

[40]  Bonnie F. Sloane,et al.  Interaction of Human Breast Fibroblasts with Collagen I Increases Secretion of Procathepsin B* , 2002, The Journal of Biological Chemistry.

[41]  B. Olson,et al.  Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .

[42]  E. Sage,et al.  SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.

[43]  M. Herlyn,et al.  Dynamics of intercellular communication during melanoma development. , 2000, Molecular medicine today.

[44]  W. Couser,et al.  SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[45]  Bonnie F. Sloane,et al.  Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. , 1999, European journal of biochemistry.

[46]  T. Mikkelsen,et al.  Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.

[47]  D. Massi,et al.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.

[48]  R. Timpl,et al.  Limited Cleavage of Extracellular Matrix Protein BM-40 by Matrix Metalloproteinases Increases Its Affinity for Collagens* , 1997, The Journal of Biological Chemistry.

[49]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[50]  O. Podhajcer,et al.  The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.

[51]  R. Huber,et al.  Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. , 1995, Biochemistry.

[52]  M. Abrahamson,et al.  Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase. , 1994, Biochimica et biophysica acta.

[53]  M. Reed,et al.  TGF‐β1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors , 1994 .

[54]  Anushya Muruganujan,et al.  PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification , 2003, Nucleic Acids Res..

[55]  R. Brekken,et al.  SPARC, a matricellular protein: at the crossroads of cell-matrix communication. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[56]  M. Reed,et al.  Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. , 2000, Kidney international.